Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis

Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis

Approved systemic treatments for children with atopic dermatitis (AD) are limited. To report dupilumab (DPL) efficacy and safety in a subgroup of children with severe AD. LIBERTY AD PRESCHOOL (NCT03346434 part B), a double-blind, randomized, placebo (PBO)-controlled, 16-week (wk) phase 3 study, enro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Revue française d'allergologie (2009) 2023-04, Vol.63 (3), p.103411, Article 103411
Hauptverfasser: Paller, A.S., Pinter, A., Lee, L. Wine, Aschoff, R., Zdybski, J., Schnopp, C., Rossi, A.B., Praestgaard, A., Bansal, A., Shumel, B., Prescilla, R., Bastian, M.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Approved systemic treatments for children with atopic dermatitis (AD) are limited. To report dupilumab (DPL) efficacy and safety in a subgroup of children with severe AD. LIBERTY AD PRESCHOOL (NCT03346434 part B), a double-blind, randomized, placebo (PBO)-controlled, 16-week (wk) phase 3 study, enrolled patients (pts; 6 months–5 years) with inadequately controlled moderate-to-severe AD. Pts received DPL 200/300mg (baseline [BL] weight 5–
ISSN:1877-0320
1877-0320
DOI:10.1016/j.reval.2023.103411